Latest News On Clinical Trials
- PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Radiation: Prophylactic Irradiation of Tracts (PIT)
Sponsors: Christie Hospital NHS Foundation Trust; Colin Lunt; Christie Hospital NHS Foundation Trust
Not yet recruiting - verified May 2012 - Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Condition: Malignant Peritoneal Mesothelioma
Interventions: Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis
Sponsors: University of Chicago; University of Chicago; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Ganetespib With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Condition: Lung Cancer - Malignant Pleural Mesothelioma
Interventions: Drug: Ganetespib; Drug: Placebo
Sponsors: University College, London; University College, London; Cancer Research UK
Not yet recruiting - verified May 2012 - Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Condition: Mesothelioma
Intervention:
Sponsors: Wake Forest University; Wake Forest University; University of Pennsylvania; Mayo Clinic; New York University School of Medicine; Johns Hopkins University; Mount Sinai School of Medicine; Memorial Sloan-Kettering Cancer Center; Mesothelioma Applied Research Foundation, Inc.
Recruiting - verified May 2012 - Treating Cancer With Anti-mesothelin Modified Lymphocytes
Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Condition: Cancer
Interventions: Drug: HGS1036 + Paclitaxel + Carboplatin; Drug: HGS1036 + Cisplatin + Etoposide; Drug: HGS1036 + Docetaxel; Drug: HGS1036 + Pemetrexed
Sponsors: Human Genome Sciences; Human Genome Sciences
Not yet recruiting - verified May 2012 - A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: PF-03446962
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Amatuximab for High Mesothelin Cancers
Conditions: Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies
Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Mesothelioma; Esophageal Cancer; Gastric Cancer; Liver Cancer; Biliary Cancer
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: ADI-PEG 20
Sponsors: Barts & The London NHS Trust; Barts & The London NHS Trust; Cancer Research UK; UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination
Recruiting - verified May 2012 - Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Conditions: Mesolthelioma; Esophageal Cancer; Lung Cancer
Interventions: Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Condition: Mesothelioma
Intervention: Drug: Zometa (zoledronic acid)
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Novartis Pharmaceuticals
Recruiting - verified May 2012 - A Study in Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: LY2603618
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
